ADXN earnings: next report 2026-08-24, real EPS beat/miss history, analyst consensus Buy, P/E -0.72. Updated 2026-07-23.
Addex Therapeutics (ADXN) Research Hub
Addex Therapeutics (ADXN) trades on NASDAQ, CH in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.49 USD (-3.32%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.72, market cap 0.00B. This hub links to the full technical, earnings and options research available for ADXN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CH |
| Last close | 3.49 USD (-3.32%) |
| 52-week range | 3.36 USD – 7.08 USD |
| Trend regime | Range |
| 14-day RSI | 16.9 (Oversold) |
| Trailing P/E | -0.72 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-24 |
Available research for ADXN
Covered Call on ADXN: how it works, illustrative setup around the real 3.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADXN: how it works, illustrative setup around the real 3.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADXN: how it works, illustrative setup around the real 3.49 USD price, max profit/loss, breakeven and when to use it. Educational.
ADXN technical analysis: range, last 3.49 USD, RSI 16.9, 52w range 3.36 USD–7.08 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ADXN in?
Addex Therapeutics (ADXN) is classified under Healthcare (Biotechnology), listed on NASDAQ, CH.
Is ADXN in an uptrend or downtrend?
As of 2026-09-11, ADXN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADXN's trailing P/E ratio?
ADXN's trailing P/E is -0.72, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ADXN next report earnings?
ADXN is next scheduled to report earnings on 2026-08-24.